Abstract
Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. There is limited data on the efficacy of the COVID vaccines in lymphoma patients, and to suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody titer following the primary COVID vaccination series. The primary series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate (UVA) and multivariate (MVA) analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); and 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p=0.04). Lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: A Della Pia, G Kim, J Ahn, Y Liu, S Kats, M Koropsak, B Lukasik, A Contractor, K Amin, L Ayyagari, C Zhao, A Gupta, M Batistick - none L Leslie: Consultancy and/or advisory committee: Seattle Genetics, KitePharma, Pharmacyclics/Janssen, AstraZeneca, Bayer, ADC Therapeutics, AbbVie, TG Therapeutics Speakers Bureau: Celgene/Bristol Myers Squibb, BeiGene, Epizyme, Karyopharm A Goy: Consultancy, Honoraria and/or speakers Bureau: Pharmacyclics, Jassen, Celgene, Novartis, Hoffman la Roche, Novartis, Celgene, Kite, Pharmacyclics/Abbvie, Elsevier?s Practice Update Oncology, Clinical Advances in Hematology & Oncology, Medscape, Physicians Education Resource, LLC, Rosewell Park, OncLive Peer Exchange, Michael J Hennessey Associates, inc., BMS, Xcenda, MorphoSys, AstraZeneca Research Funding: Janssen, Acerta, Celgene, Constellation, Genentech, Hoffman la Roche, Infinity Pharmaceuticals, MorphoSys, Karyopharm, Kite, Pharmacyclics, AstraZeneca, Verastem, Seattle Genetics, BMS Advisory Board: Janssen, Vincerx pharma, Janssen, Kite Pharma, Elsevier?s Practice Update Oncology, Gilead, Abbvie, Pharmacyclics, BMS, AstraZeneca, Alloplex Board of Directors: COTA, Genomix Testing Cooperative, Resilience Stock: COTA, Genomic Testing Cooperative, Alloplex, Resilience T Feldman: Consultancy, Honoraria and/or speakers Bureau: Abbvie, ADC Therapeutics, BMS, Celgene, Janssen, Pharmacyclics, Seattle Genetics, Takeda Advisory Board: Abbvie, ADC Therapeutics, Daiichi Sankyo, Genmab, Karyopharm, KITE, Kyowa Kirin, Morphosys A Ip: Consultancy, Honoraria and/or speaker Bureau: TG Therapeutics, AstraZeneca Advisory Board: Secura Bio
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board (IRB) approval was obtained under Hackensack Meridian Health. The requirement for patient informed consent was waived by the IRB as this project represented a non-interventional study utilizing routinely collected data for secondary research purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The study involves a review of the electronic medical records of lymphoma patients who received the COVID vaccine. The research data set has removed most, but not all protected health information (for example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore, for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share portions of the data for appropriate review. Requests can be made through the corresponding author or directly to representatives of Hackensack Meridian Health (Dr Andrew Ip Email: Andrew.Ip{at}hmhn.org).
